4.8 Article

Protective Effect of Human Leukocyte Antigen B27 in Hepatitis C Virus Infection Requires the Presence of a Genotype-Specific Immunodominant CD8+ T-Cell Epitope

Journal

HEPATOLOGY
Volume 51, Issue 1, Pages 54-62

Publisher

WILEY
DOI: 10.1002/hep.23275

Keywords

-

Funding

  1. Bundesministerium fur Bildung und Forschung (BMBF) [01KI0793, 01EO0803]
  2. Deutsche Forschungsgemeinschaft [TH 719/3-1]
  3. [FOR 1202]
  4. [TI323/3-1]
  5. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066345] Funding Source: NIH RePORTER
  6. Medical Research Council [G1000800g, G108/601, MC_U137884185] Funding Source: researchfish
  7. MRC [G108/601, MC_U137884185] Funding Source: UKRI

Ask authors/readers for more resources

Human leukocyte antigen B27 (HLA-B27) is associated with protection in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection. This protective role is linked to single immunodominant HI.A-B27-restricted CD8+ T-cell epitopes in both infections. In order to define the relative contribution of a specific HLA-B27-restricted epitope to the natural course of HCV infection, we compared the biological impact of the highly conserved HCV genotype I epitope, for which the protective role has been described, with the corresponding region in genotype 3 that differs in its sequence by three amino acid residues. The genotype 3a peptide was not recognized by CD8+ T cells specific for the genotype 1 peptide. Furthermore, patients with acute or chronic infection with HCV genotype 3a did not mount T-cell responses to this epitope region, and their autologous viral sequences showed no evidence of T-cell pressure. Finally, we found a significantly higher frequency of HLA-B27 positivity in patients with chronic HCV genotype 3a infection compared to genotype I infection, indicating that there is no protection by HLA-B27 in HCV genotype 3 infection. Conclusion: Our data indicate that the protective effect of HLA-B27 is limited to HCV genotype I infection and does not expand to other genotypes such as genotype 3a. This can most likely be explained by intergenotype sequence diversity leading to the loss of the immunodominant HLA-B27 epitope in viral strains other than genotype 1. Our results underline the central role of a single HLA-B27-restricted epitope-specific CD8+ T-cell response in mediating protection in HCV genotype I infection. (HEPATOLOGY 2010;51:54-62.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Defining the key intrahepatic gene networks in HCV infection driven by sex

Emanuele Marchi, Narayan Ramamurthy, M. Azim Ansari, Caroline E. Harrer, Eleanor Barnes, Paul Klenerman

Summary: This study aimed to profile the transcriptomics of HCV-infected livers and assess the effect of major predictors of clinical outcome such as IFNL4 host genotype and sex. The results showed that underlying cirrhotic state had the most substantial impact on transcriptional responses, and sex and IL28B/IFNL4 genotype also played important roles in antiviral responses.
Article Gastroenterology & Hepatology

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study

Stephan Buch, Hamish Innes, Philipp Ludwig Lutz, Hans Dieter Nischalke, Jens U. Marquardt, Janett Fischer, Karl Heinz Weiss, Jonas Rosendahl, Astrid Marot, Marcin Krawczyk, Markus Casper, Frank Lammert, Florian Eyer, Arndt Vogel, Silke Marhenke, Johann von Felden, Rohini Sharma, Stephen Rahul Atkinson, Andrew McQuillin, Jacob Nattermann, Clemens Schafmayer, Andre Franke, Christian Strassburg, Marcella Rietschel, Heidi Altmann, Stefan Sulk, Veera Raghavan Thangapandi, Mario Brosch, Carolin Lackner, Rudolf E. Stauber, Ali Canbay, Alexander Link, Thomas Reiberger, Mattias Mandorfer, Georg Semmler, Bernhard Scheiner, Christian Datz, Stefano Romeo, Stefano Ginanni Corradini, William Lucien Irving, Joanne R. Morling, Indra Neil Guha, Eleanor Barnes, M. Azim Ansari, Jocelyn Quistrebert, Luca Valenti, Sacha A. Mueller, Marsha Yvonne Morgan, Jean-Francois Dufour, Jonel Trebicka, Thomas Berg, Pierre Deltenre, Sebastian Mueller, Jochen Hampe, Felix Stickel

Summary: This study identifies rs2242652 in TERT as a novel protective factor for HCC in patients with alcohol-related cirrhosis.
Review Gastroenterology & Hepatology

Implementation of a controlled human infection model for evaluation of HCV vaccine candidates

Eleanor Barnes, Graham S. Cooke, Georg M. Lauer, Raymond T. Chung

Summary: This article discusses the global health concern of hepatitis C virus (HCV) and the limitations of using directly acting antiviral (DAA) drugs for treatment. Without an effective HCV vaccine, the authors argue that the development of a controlled human infection model (CHIM) for HCV is crucial. They propose a study design for the HCV CHIM, including the selection of volunteers, development of an infectious inoculum, evaluation of immune and viral parameters, etc. The authors conclude that an HCV CHIM is realistic and can address safety and ethical concerns, and it is difficult to envision the development of an HCV vaccine without it.

HEPATOLOGY (2023)

Article Immunology

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (HIV)

Sarah Fidler, Julie Fox, Timothy Tipoe, Stephanie Longet, Tom Tipton, Movin Abeywickrema, Sandra Adele, Jasmini Alagaratnam, Mohammad Ali, Parvinder K. Aley, Suhail Aslam, Anbhu Balasubramanian, Anna Bara, Tanveer Bawa, Anthony Brown, Helen Brown, Federica Cappuccini, Sophie Davies, Jamie Fowler, Leila Godfrey, Anna L. Goodman, Kathrine Hilario, Carl-Philipp Hackstein, Moncy Mathew, Yama F. Mujadidi, Alice Packham, Claire Petersen, Emma Plested, Katrina M. Pollock, Maheshi N. Ramasamy, Hannah Robinson, Nicola Robinson, Patpong Rongkard, Helen Sanders, Teona Serafimova, Niamh Spence, Anele Waters, Danielle Woods, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Alan Winston, Adrian V. S. Hill, Sarah C. Gilbert, Miles Carroll, Andrew J. Pollard, Teresa Lambe, Ane Ogbe, John Frater

Summary: People with HIV on antiretroviral therapy and good CD4 T-cell counts can generate effective immune responses against SARS-CoV-2 after vaccination. A third vaccine dose can significantly enhance B- and T-cell immunity, including responses to known variants of concern.

CLINICAL INFECTIOUS DISEASES (2023)

Editorial Material Gastroenterology & Hepatology

Prophylactic vaccination against hepatitis D virus superinfection: from fiction to reality? Comment

Julia Lang-Meli, Christoph Neumann-Haefelin

Article Gastroenterology & Hepatology

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

Julia Dietz, Beat Muellhaupt, Peter Buggisch, Christiana Graf, Kai-Henrik Peiffer, Katrin Matschenz, Joern M. Schattenberg, Christoph Antoni, Stefan Mauss, Claus Niederau, Thomas Discher, Janina Trauth, Georg Dultz, Julian Schulze zur Wiesch, Felix Piecha, Hartwig Klinker, Tobias Mueller, Thomas Berg, Christoph Neumann-Haefelin, Christoph P. Berg, Stefan Zeuzem, Christoph Sarrazin

Summary: This study evaluated the long-term persistence of resistance-associated substitutions (RASs) in HCV patients treated with DAAs. Low-to medium-level RASs were found to persist over time, while high-level resistant RASs gradually disappeared. Different patterns of RAS persistence according to HCV subtype could have implications for retreatment with first-generation DAAs and for global HCV elimination goals.

JOURNAL OF HEPATOLOGY (2023)

Article Immunology

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults

C. Green, J. McGinley, C. Sande, S. Capone, S. Makvandi-Nejad, A. Vitelli, L. Silva-Reyes, S. Bibi, C. Otasowie, D. Sheerin, A. Thompson, C. Dold, P. Klenerman, E. Barnes, L. Dorrell, C. Rollier, A. Pollard, D. O'Connor

Summary: In this immunological study, cohorts of healthy younger and older adults were immunized with an adenovirus-vectored RSV vaccine either intramuscularly or intranasally. Differential gene expression was observed in blood samples after intramuscular prime vaccination, but not after intranasal prime vaccination. Intranasally primed participants showed more gene expression changes upon boosting. The gene expression changes mainly involved immune-related biological processes.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2023)

Review Microbiology

SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants

David B. Reeg, Maike Hofmann, Christoph Neumann-Haefelin, Robert Thimme, Hendrik Luxenburger

Summary: Cellular immunity is crucial for controlling SARS-CoV-2 infection and vaccination induces T cell responses that protect against severe COVID-19. However, immunocompromised individuals have impaired virus-specific immune responses to both natural infection and vaccination. This review focuses on cancer patients, people living with HIV, and solid organ transplant recipients, providing an overview of their SARS-CoV-2-specific cellular immune responses and their clinical implications.

PATHOGENS (2023)

Article Immunology

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination

Sile A. Johnson, Eloise Phillips, Sandra Adele, Stephanie Longet, Tom Malone, Chris Mason, Lizzie Stafford, Anni Jamsen, Siobhan Gardiner, Alexandra Deeks, Janice Neo, Emily J. Blurton, Jemima White, Muhammed Ali, Barbara Kronsteiner, Joseph D. Wilson, Donal T. Skelly, Katie Jeffery, Christopher P. Conlon, Philip Goulder, Eleanor PITCH Consortium, Miles Carroll, Eleanor Barnes, Paul Klenerman, Susanna J. Dunachie

Summary: PITCH ELISpot S1 + S2 had greater sensitivity for SARS-CoV-2 specific T-cell responses compared with the QuantiFERON SARS-CoV-2 assay tube Ag3, except for the acute infection group. The QuantiFERON SARS-CoV-2 assay showed potential as a T-cell evaluation tool soon after SARS-CoV-2 infection but has lower sensitivity for use in reliable evaluation of vaccination or more distant infection.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2023)

Article Gastroenterology & Hepatology

A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico

Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.

JOURNAL OF HEPATOLOGY (2023)

Article Medicine, General & Internal

Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database

Weiqi Liao, Carol A. C. Coupland, Hamish Innes, Peter Jepsen, Philippa C. Matthews, Cori Campbell, The DeLIVER consortium DeLIVER consortium, Eleanor Barnes, Julia Hippisley-Cox

Summary: This study aims to understand the disparities in epidemiology and clinical pathways of primary liver cancer in England. The findings show that age, sex, socioeconomic deprivation, ethnicity, and geographical regions are all significantly associated with liver cancer incidence. Patients aged 80 years and above have a higher risk of being diagnosed at late stages and have poorer survival rates. Men are at a higher risk of liver cancer than women, and survival rates are generally poor.

ECLINICALMEDICINE (2023)

Article Medicine, Research & Experimental

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

Shona C. Moore, Barbara Kronsteiner, Stephanie Longet, Sandra Adele, Alexandra S. Deeks, Chang Liu, Wanwisa Dejnirattisai, Laura Silva Reyes, Naomi Meardon, Sian Faustini, Saly Al-Taei, Tom Tipton, Luisa M. Hering, Adrienn Angyal, Rebecca Brown, Alexander R. Nicols, Susan L. Dobson, Piyada Supasa, Aekkachai Tuekprakhon, Andrew Cross, Jessica K. Tyerman, Hailey Hornsby, Irina Grouneva, Megan Plowright, Peijun Zhang, Thomas A. H. Newman, Jeremy M. Nell, Priyanka Abraham, Mohammad Ali, Tom Malone, Isabel Neale, Eloise Phillips, Joseph D. Wilson, Sam M. Murray, Martha Zewdie, Adrian Shields, Emily C. Horner, Lucy H. Booth, Lizzie Stafford, Sagida Bibi, Daniel G. Wootton, Alexander J. Mentzer, Christopher P. Conlon, Katie Jeffery, Philippa C. Matthews, Andrew J. Pollard, Anthony Brown, Sarah L. Rowland-Jones, Juthathip Mongkolsapaya, Rebecca P. Payne, Christina Dold, Teresa Lambe, James E. D. Thaventhiran, Gavin Screaton, Eleanor Barnes, Susan Hopkins, Victoria Hall, Christopher J. A. Ducan, Alex Richter, Miles Carroll, Thushan I. de Silva, Paul Klenerman, Susann Dunachie, Lance Turtle, PITCH Consortium

Summary: In this study, the researchers observed the immune response changes in 684 UK healthcare workers after receiving two doses of BNT162b2 or AZD1222 vaccines during a follow-up period of 6-9 months. The study found that the antibody and memory B cell responses were relatively stable, while the levels of binding and neutralizing antibodies declined. The study also found that individuals with prior infection had stronger and broader T cell responses to the vaccine, especially after receiving the third dose.
Article Biochemistry & Molecular Biology

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, Charlotte Gaskell, Stefan Siebert, Thushan I. de Silva, Sam M. Murray, Daniel Rea, John A. Snowden, Miles Carroll, Sarah Pirrie, Sarah J. Bowden, Susanna J. Dunachie, Alex Richter, Zixiang Lim, Jack Satsangi, Gordon Cook, Ann Pope, Ana Hughes, Molly Harrison, Sean H. Lim, Paul Miller, Paul Klenerman, Pitch Consortium, Neil Basu, Ashley Gilmour, Sophie Irwin, Georgina Meacham, Thomas Marjot, Stavros Dimitriadis, Peter Kelleher, Maria Prendecki, Candice Clarke, Paige Mortimer, Stacey McIntyre, Rachael Selby, Naomi Meardon, Dung Nguyen, Tom Tipton, Stephanie Longet, Stephen Laidlaw, Kim Orchard, Georgina Ireland, David Thomas, Pamela Kearns, Amanda Kirkham, Iain B. McInnes

Summary: Serological analysis and infection outcomes of 2,686 participants with immune-suppressive diseases who received two COVID-19 vaccines revealed specific clinical phenotypes that might benefit from targeted COVID-19 therapeutic strategies. Some patients failed to develop anti-SARS-CoV-2 antibodies, with the highest vaccine failure rates observed in ANCA-associated vasculitis, hemodialysis, and solid organ transplant recipients. Decreased serological and T cell responses were associated with severe COVID-19. In summary, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.

NATURE MEDICINE (2023)

Article Medicine, General & Internal

Tiza-Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study

Stephanie Vollmer-Raschdorf, Jassin Rashidi-Alavijeh, Sebastian Voigt, Hartmut Hengel, Benjamin Borchardt, Daniela Huzly, Eva-Maria Huessler, Juergen In Der Schmitten, Anne Halenius, Katharina Willuweit, Suzan Botzenhardt, Mirko Trilling, Tobias Boettler, Dorothea Dehnen

Summary: This study aims to investigate the immune responses to the Shingrix vaccine in different patient populations and compare their vaccine reactions. The study will collect blood samples from 308 patients at seven different time points and analyze varicella zoster virus (VZV) and glycoprotein E (gE)-specific IgG and T cell responses. The primary outcome is to measure and compare the vaccine responses based on the type and degree of immunosuppression using antibody detection assays. Secondary outcomes include comparing the CD4(+) T cell responses and the severity of vaccination reactions among the three patient cohorts. The study also aims to find a potential association between VZV immune responses and clinical protection against shingles.

BMJ OPEN (2023)

No Data Available